Stock Research: Adaptive Biotechnologies

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Adaptive Biotechnologies

NSQ:ADPT US00650F1093
73
  • Value
    43
  • Growth
    62
  • Safety
    Safety
    74
  • Combined
    70
  • Sentiment
    65
  • 360° View
    360° View
    73
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Adaptive Biotechnologies Corporation is a biotechnology company focused on harnessing the adaptive immune system for disease diagnosis and treatment. It operates in the fields of Minimal Residual Disease (MRD) with its clonoSEQ clinical diagnostic test, and Immune Medicine, discovering and developing immune-based therapies for cancer and autoimmune diseases. In the last fiscal year, the company had 619 employees, a market cap of $1701 million, profits of $107 million, and revenue of $179 million.

more

ANALYSIS: With an Obermatt 360° View of 73 (better than 73% compared with alternatives), overall professional sentiment and financial characteristics for the stock Adaptive Biotechnologies are above average. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Adaptive Biotechnologies. The consolidated Growth Rank has a good rank of 62, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 62% of competitors in the same industry. The consolidated Safety Rank at 74 means that the company has a financing structure that is safer than 74% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 65, which means that professional investors are more optimistic about the stock than for 65% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 43, meaning that the share price of Adaptive Biotechnologies is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 57% of alternative stocks in the same industry. ...read more

more
Index
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Aug-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
43 6 55 25
Growth
62 99 71 29
Safety
Safety
74 8 98 87
Sentiment
65 80 57 47
360° View
360° View
73 47 94 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
36 64 67 42
Opinions Change
50 28 50 50
Pro Holdings
n/a 82 39 83
Market Pulse
51 75 49 26
Sentiment
65 80 57 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
43 6 55 25
Growth
62 99 71 29
Safety Safety
74 8 98 87
Combined
70 19 94 56
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
55 39 59 17
Price vs. Earnings (P/E)
100 60 60 10
Price vs. Book (P/B)
7 4 60 55
Dividend Yield
1 1 1 1
Value
43 6 55 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
39 91 88 70
Profit Growth
77 60 61 28
Capital Growth
43 88 58 70
Stock Returns
63 95 21 9
Growth
62 99 71 29
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
9 30 100 100
Refinancing
83 23 75 49
Liquidity
82 28 26 n/a
Safety Safety
74 8 98 87

Similar Stocks

Discover high‑ranked alternatives to Adaptive Biotechnologies and broaden your portfolio horizons.

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Global Payments

NYQ:GPN
Country: USA
Industry: Other Financial Services
Size: X-Large
Full Stock Analysis

Merck (USA)

NYQ:MRK
Country: USA
Industry: Pharmaceuticals
Size: XX-Large
Full Stock Analysis

Micron

NSQ:MU
Country: USA
Industry: Semiconductors
Size: XX-Large
Full Stock Analysis

Frequently Asked
Questions

This stock offers a high growth opportunity with safe financing and positive sentiment. It is typically expensive (low Value Rank), as investors pay a premium for high performance. It is for growth-focused investors comfortable paying a premium for a stock with strong future momentum.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: